247 related articles for article (PubMed ID: 32233322)
21. Hypereosinophilic syndromes.
Roufosse FE; Goldman M; Cogan E
Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
[TBL] [Abstract][Full Text] [Related]
22. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
23. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
Hellmich B; Holl-Ulrich K; Gross WL
Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
[TBL] [Abstract][Full Text] [Related]
24. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
25. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
26. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
[TBL] [Abstract][Full Text] [Related]
27. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
28. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Stone RM; Gilliland DG; Klion AD
Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
[TBL] [Abstract][Full Text] [Related]
29. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
30. Cough in hypereosinophilic syndrome: case report and literature review.
Xie J; Zhang J; Zhang X; Zhang Q; Chung KF; Wang C; Lai K
BMC Pulm Med; 2020 Apr; 20(1):90. PubMed ID: 32293378
[TBL] [Abstract][Full Text] [Related]
31. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.
Groh M; Rohmer J; Etienne N; Abou Chahla W; Baudet A; Chan Hew Wai A; Chenivesse C; Clisson Rusek I; Cottin V; Decamp M; De Groote P; Delahousse F; Duployez N; Faguer S; Gottrand F; Huang F; Leblanc T; Magnan A; Martin T; Mortuaire G; Néel A; Paris L; Petit A; Rossignol J; Schleinitz N; Soret-Dulphy J; Staumont-Salle D; Terrier B; Terriou L; Viallard JF; Lefèvre G; Kahn JE
Orphanet J Rare Dis; 2023 Apr; 18(1):100. PubMed ID: 37122022
[TBL] [Abstract][Full Text] [Related]
32. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
33. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
35. Clinical management of the hypereosinophilic syndromes.
Cogan E; Roufosse F
Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
[TBL] [Abstract][Full Text] [Related]
36. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
Roufosse F; Goldman M; Cogan E
Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
[TBL] [Abstract][Full Text] [Related]
37. Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.
Yamada Y; Rothenberg ME; Cancelas JA
Transl Oncogenomics; 2006; 1():53-63. PubMed ID: 23662039
[TBL] [Abstract][Full Text] [Related]
38. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
39. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
Iurlo A; Cattaneo D
Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195
[TBL] [Abstract][Full Text] [Related]
40. [The Lymphoid Variant of HES (L-HES) as Differential Diagnose of Severe Asthma in Childhood].
Leu T; Rauthe S; Wirth C; Simon HU; Kunzmann V; Hebestreit H; Kunzmann S
Klin Padiatr; 2016 Nov; 228(6-07):319-324. PubMed ID: 27846662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
